ID
45680
Beschreibung
Principal Investigator: Matthew J. Ellis, MD, PhD, Baylor College of Medicine, Houston, TX, USA MeSH: Breast Neoplasms https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001234 Targeted massively parallel sequencing analysis was conducted on DNA extracted from archived 22-28 year old, formalin-fixed primary breast tumors from 625 patents from British Columbia treated with five years of adjuvant tamoxifen monotherapy and followed for over 10 years. Genes were selected for targeted sequencing by review of existing large-scale breast cancer sequencing studies and breast cancer literature. In total, 83 genes were identified and 3,029 probes were designed to tile across all known exons. Illumina sequencing libraries were constructed, indexed, pooled, and enriched for target sequences by hybrid-capture followed by sequencing of paired-end 100bp reads. All samples met minimum quality controls of 80% targeted space covered at 20X or greater. On average, each sample had 336M aligned bases and a mean coverage of 135.8X.
Link
Stichworte
Versionen (1)
- 25.04.23 25.04.23 - Simon Heim
Rechteinhaber
Matthew J. Ellis, MD, PhD, Baylor College of Medicine, Houston, TX, USA
Hochgeladen am
25. April 2023
DOI
Für eine Beantragung loggen Sie sich ein.
Lizenz
Creative Commons BY 4.0
Modell Kommentare :
Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.
Itemgroup Kommentare für :
Item Kommentare für :
Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.
dbGaP phs001234 Sequence of Primary ER+ Breast Tumors Treated with 5 Years of Tamoxifen
Eligibility Criteria
- StudyEvent: SEV1
- Eligibility Criteria
- The subject consent file includes subject IDs, consent information, and affection status of the subject for ER-positive invasive breast cancer.
- This data table contains a mapping of study subject IDs to sample IDs. Samples are the final preps submitted for genotyping, sequencing, and/or expression data. For example, if one patient (subject ID) gave one sample, and that sample was processed differently to generate 2 sequencing runs, there would be two rows, both using the same subject ID, but having 2 unique sample IDs. The data table also includes sample use.
- This sample attributes table contains sample ID, histological type, analyte type, body site, tumor status, and tissue treatment.
Ähnliche Modelle
Eligibility Criteria
- StudyEvent: SEV1
- Eligibility Criteria
- The subject consent file includes subject IDs, consent information, and affection status of the subject for ER-positive invasive breast cancer.
- This data table contains a mapping of study subject IDs to sample IDs. Samples are the final preps submitted for genotyping, sequencing, and/or expression data. For example, if one patient (subject ID) gave one sample, and that sample was processed differently to generate 2 sequencing runs, there would be two rows, both using the same subject ID, but having 2 unique sample IDs. The data table also includes sample use.
- This sample attributes table contains sample ID, histological type, analyte type, body site, tumor status, and tissue treatment.
C0680251 (UMLS CUI [1,2])
C0677930 (UMLS CUI [1,2])
C2938924 (UMLS CUI [1,3])
C0853879 (UMLS CUI [1,4])
C0079946 (UMLS CUI [1,5])
C0006193 (UMLS CUI [1,6])
C0087111 (UMLS CUI [2,1])
C0872291 (UMLS CUI [2,2])
C1522673 (UMLS CUI [2,3])
C0039286 (UMLS CUI [2,4])
C1298908 (UMLS CUI [2,5])
C3665472 (UMLS CUI [2,6])
C1522577 (UMLS CUI [2,7])
C2986538 (UMLS CUI [2,8])
C4551700 (UMLS CUI [2,9])